Volume Alert - CLDX 18.49 Celldex Therapeutics Inc $CLDX Hit a high today of 18.71 Closing the day 10:30 at 18.49 +0.77 +4.35% With a day low of 17.47 and a total volume of 1,610,876.
CLDX Recent Posts: http://investorshangout.com/Celldex-Therapeut...LDX-53702/
CLDX Celldex Therapeutics Inc Recent Headline News
Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU - Analyst Blog
Arpita Dutt - Zacks Investment Research - 1 hr 57 mins ago
Regulatory updates from Gilead (GILD) and Regeneron (REGN) and Geron's (GERN) deal with J&J were the highlights last week in the biotech sector.
GILD: 102.10 (-1.61), GERN: 3.20 (+0.03), CLDX: 19.06 (+1.34), CYTR: 2.69 (+0.17), AMGN: 162.63 (+0.39), ABBV: 65.67 (-0.38), REGN: 417.20 (+3.98)
Celldex Therapeutics Surges on Positive Rindopepimut Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:05PM CST
Celldex Therapeutics announced encouraging interim update from the phase II ReACT study evaluating the use of rindopepimut.
ACT: 268.40 (-1.20), CLDX: 19.06 (+1.34), ABBV: 65.67 (-0.38)
Why Celldex Therapeutics' Stock Is Now Ready For Takeoff
Brian Nichols - at Seeking Alpha - Tue Nov 18, 1:44PM CST
CLDX: 19.06 (+1.34), ALXN: 193.71 (+1.34)
Celldex Therapeutics (CLDX) Stock Sells Off Today Following Monday's Gains
at The Street - Tue Nov 18, 10:47AM CST
Shares of Celldex Therapeutics (CLDX) dipped Tuesday after the stock surged Monday following the company's announcement of positive results of its immunotherapy in treating a certain type of brain tumor.
CLDX: 19.06 (+1.34)
Celldex Therapeutics To Enter Talks With FDA
Steven Giardino - Seeking Alpha - Tue Nov 18, 9:26AM CST
On Friday, Celldex Therapeutics (NASDAQ: CLDX ) announced results from a recently near completed Ph II trial testing Rindopepimut in recurrent glioblastoma ((rGBM)). The 72 patient, randomized, placebo controlled study (gold standard of trial design)...
NWBO: 5.26 (-0.13), CLDX: 19.06 (+1.34), SRPT: 15.97 (+0.40)
Critical Alerts For Kinder Morgan, Celldex Therapeutics, Baker Hughes Inc., RF Micro Devices and SolarCity Released By InvestorsObserver
PR Newswire - Tue Nov 18, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for KMI, CLDX, BHI, RFMD and SCTY.
KMI: 40.68 (+0.27), SCTY: 54.93 (-0.71), CLDX: 19.06 (+1.34), RFMD: 13.73 (-0.02), BHI: 63.25 (-0.30)
Celldex Therapeutics, Inc. (CLDX) in Focus: Stock Soars 28.9% - Tale of the Tape
Vaishali Doshi Shah - Zacks Investment Research - Tue Nov 18, 8:18AM CST
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as the company saw its shares rise by almost 29% on the day.
ANIP: 56.54 (+0.88), CLDX: 19.06 (+1.34), AMAG: 35.50 (+0.16), AFFX: 8.75 (-0.83)
Look for Shares of Celldex Therapeutics to Potentially Pullback after Yesterday's 28.88% Rise
Comtex SmarTrend(R) - Mon Nov 17, 4:40PM CST
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $16.30 to a high of $19.48. Yesterday, the shares gained 28.9%, which took the trading range above the 3-day high of $15.27 on volume of 22.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CLDX: 19.06 (+1.34)
Earnings Flashback: Since Reporting Quarterly Results 1 Week Ago Celldex Therapeutics Is Down 14.6% (CLDX)
Comtex SmarTrend(R) - Mon Nov 17, 3:58PM CST
When Celldex Therapeutics (NASDAQ:CLDX) reported earnings a week ago on November 4th, 2014, analysts, on average, expected the company to report a loss of $0.33 on sales of $324.0 thousand. Celldex Therapeutics actually reported a loss of $0.31 per share on sales of $1.1 million, beating EPS estimates by $0.02 and beating revenue estimates by $0.8 million. Shares of Celldex Therapeutics have slipped from $16.58 to $14.16, representing a loss of 14.6%, since the company reported earnings 13 days ago.
CLDX: 19.06 (+1.34)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:47AM CST
CADC: 5.11 (-0.32), ANV: 1.76 (-0.28), BONE: 3.14 (-0.02), WLH: 19.17 (+0.01), CLDX: 19.06 (+1.34), ENZY: 8.20 (-0.05), TGEN: 5.54 (-0.68), CHOP: 2.10 (-0.03), MSBF: 9.90 (-0.01), NVGN: 1.75 (-0.05), DWA: 22.54 (+0.06), WHX: 2.26 (-0.08), VYFC: 19.69 (-0.06), VGGL: 3.18 (-0.23), SNSS: 2.18 (+0.11), DNR: 9.85 (-0.16), MOBI: 5.58 (-0.31), VPCO: 1.58 (-0.01), FOLD: 6.68 (-0.07), ATEA: 1.35 (-0.11)
Celldex Therapeutics (CLDX) Stock Surges Following Brain Tumor Immunotherapy Results
at The Street - Mon Nov 17, 10:02AM CST
Shares of Celldex Therapeutics (CLDX) were up in morning trading Monday after the company announced positive results of its immunotherapy in treating a certain type of brain tumor.
CLDX: 19.06 (+1.34)
Celldex Therapeutics: Interim Results For Phase 2 ReACT Trial Are Very Encouraging
Smith On Stocks - at Seeking Alpha - Mon Nov 17, 9:28AM CST
CLDX: 19.06 (+1.34)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:15AM CST
CADC: 5.11 (-0.32), INO: 9.55 (-0.31), CLDX: 19.06 (+1.34), HAL: 48.45 (-0.09), ROX: 1.57 (-0.21), SNSS: 2.18 (+0.11), DNR: 9.85 (-0.16), DWA: 22.54 (+0.06), GSAT: 2.66 (+0.11), CMGE: 25.46 (-0.70), FOLD: 6.68 (-0.07), BHI: 63.27 (-0.28)
Celldex up premarket on positive rindopepimut data
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 7:57AM CST
CLDX: 19.06 (+1.34)
Biotech Equities Technical Coverage - Orexigen Therapeutics, Novavax, Sunesis Pharma, Celldex Therapeutics, and Navidea Biopharma
PR Newswire - Mon Nov 17, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Orexigen Therapeutics Inc. (NASDAQ: OREX), Novavax Inc. (NASDAQ: NVAX), Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, November 14, 2014, the NASDAQ Composite ended at 4,688.54, up 0.18%, the Dow Jones Industrial Average edged 0.10% lower, to finish the day at 17,634.74, and the S&P 500 closed at 2,039.82, up 0.02%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 777.26, down 0.83%, while the index has advanced 9.80% in the last one month. Register for your complimentary reports on these five stocks at:
OREX: 5.72 (+0.10), NAVB: 1.20 (unch), NVAX: 4.96 (-0.05), CLDX: 19.06 (+1.34), SNSS: 2.18 (+0.11)
Celldex Therapeutics' (CLDX) CEO Presents Phase 2 ReACT Interim Data at the Society for Neuro-Oncology Annual Meeting (Transcript)
SA Transcripts - at Seeking Alpha - Fri Nov 14, 10:53PM CST
CLDX: 19.06 (+1.34)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 4:38PM CST
HK: 2.90 (+0.02), NTES: 100.11 (-1.79), CIG: 4.88 (-0.01), TSRO: 30.75 (-0.70), DDD: 36.01 (+0.64), CLDX: 19.06 (+1.34), SCMP: 11.95 (-0.10), BVN: 9.76 (-0.01), ABGB: 15.23 (+0.83), SSE: 10.33 (-0.07)
Interim Update from Randomized Phase 2 ReACT Study of Rindopepimut in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Survival Benefit
GlobeNewswire - Fri Nov 14, 2:35PM CST
-Benefit observed across multiple endpoints in bevacizumab-naïve patients-
CLDX: 19.06 (+1.34)
Celldex Immunotherapy Prolongs Survival for Recurrent Brain Tumor Patients
at The Street - Fri Nov 14, 2:35PM CST
Positive data presented Friday, particularly the statistically significant survival benefit favoring patients treated with rindopepimut, has Celldex planning -- cautiously -- for a conversation with the FDA about accelerated approval.
CLDX: 19.06 (+1.34)
Global Immune Checkpoint Inhibitors Market, 2014-2024: Yervoy, Opdivo and Keytruda to Achieve Blockbuster Status in the Near Future
M2 - Thu Nov 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkbg4v/immune_checkpoint) has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering. The Immune Checkpoint Inhibitors Market, 2014-2024 report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for the broad range of cancer. CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic Immune Checkpoint Inhibitor commercially available until other classes recently stepped in. The approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period. Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants. Key Highlights - The market is characterized by the presence of three marketed drugs and 25 drugs in clinical development for oncological indications. This pipeline includes two CTLA-4, eight PD-1 / PD-L1 and 18 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 30 such molecules. - BMS, with seven Immune Checkpoint Inhibitors (marketed / clinical development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck and Roche. Many university spin-offs have emerged in the past two years; their early stage research has been backed by venture funding as well. - Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have been the most sought after drug class under development. Though Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market. - Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; 2014 has already seen 12 such collaborations for a number of molecules. - We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2014 - 2024, our forecast suggests that the market will witness an annualized growth rate of 24.1%. Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Immuno-Oncology 4. Current Market Landscape 5. CTLA-4 Inhibitors: Key Molecules and Future Outlook 6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook 7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook 8. Competition in Key Indication Areas 9. Deals and Partnerships 10. Company Profiles 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - Bristol Myer Squibb - AstraZeneca - Merck & Co. - Roche / Genentech - Incyte Corporation - NewLink Genetics - arGEN-X - Seattle Genetics - Pfizer - MacroGenics - Celldex Therapeutics - CureTech - Immutep - Innate Pharma - Sorrento Therapeutics - GlaxoSmithKline - GITR, Inc. For more information visit http://www.researchandmarkets.com/research/fk...checkpoint
MRK: 59.55 (-0.34), INCY: 71.57 (+1.93), CLDX: 19.06 (+1.34), NLNK: 33.18 (+0.52), GSK: 46.32 (+0.04), BMY: 58.55 (-0.15), SRNE: 4.00 (unch)
CLDX Recent Posts: http://investorshangout.com/Celldex-Therapeut...LDX-53702/
CLDX Celldex Therapeutics Inc Recent Headline News
Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU - Analyst Blog
Arpita Dutt - Zacks Investment Research - 1 hr 57 mins ago
Regulatory updates from Gilead (GILD) and Regeneron (REGN) and Geron's (GERN) deal with J&J were the highlights last week in the biotech sector.
GILD: 102.10 (-1.61), GERN: 3.20 (+0.03), CLDX: 19.06 (+1.34), CYTR: 2.69 (+0.17), AMGN: 162.63 (+0.39), ABBV: 65.67 (-0.38), REGN: 417.20 (+3.98)
Celldex Therapeutics Surges on Positive Rindopepimut Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:05PM CST
Celldex Therapeutics announced encouraging interim update from the phase II ReACT study evaluating the use of rindopepimut.
ACT: 268.40 (-1.20), CLDX: 19.06 (+1.34), ABBV: 65.67 (-0.38)
Why Celldex Therapeutics' Stock Is Now Ready For Takeoff
Brian Nichols - at Seeking Alpha - Tue Nov 18, 1:44PM CST
CLDX: 19.06 (+1.34), ALXN: 193.71 (+1.34)
Celldex Therapeutics (CLDX) Stock Sells Off Today Following Monday's Gains
at The Street - Tue Nov 18, 10:47AM CST
Shares of Celldex Therapeutics (CLDX) dipped Tuesday after the stock surged Monday following the company's announcement of positive results of its immunotherapy in treating a certain type of brain tumor.
CLDX: 19.06 (+1.34)
Celldex Therapeutics To Enter Talks With FDA
Steven Giardino - Seeking Alpha - Tue Nov 18, 9:26AM CST
On Friday, Celldex Therapeutics (NASDAQ: CLDX ) announced results from a recently near completed Ph II trial testing Rindopepimut in recurrent glioblastoma ((rGBM)). The 72 patient, randomized, placebo controlled study (gold standard of trial design)...
NWBO: 5.26 (-0.13), CLDX: 19.06 (+1.34), SRPT: 15.97 (+0.40)
Critical Alerts For Kinder Morgan, Celldex Therapeutics, Baker Hughes Inc., RF Micro Devices and SolarCity Released By InvestorsObserver
PR Newswire - Tue Nov 18, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for KMI, CLDX, BHI, RFMD and SCTY.
KMI: 40.68 (+0.27), SCTY: 54.93 (-0.71), CLDX: 19.06 (+1.34), RFMD: 13.73 (-0.02), BHI: 63.25 (-0.30)
Celldex Therapeutics, Inc. (CLDX) in Focus: Stock Soars 28.9% - Tale of the Tape
Vaishali Doshi Shah - Zacks Investment Research - Tue Nov 18, 8:18AM CST
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as the company saw its shares rise by almost 29% on the day.
ANIP: 56.54 (+0.88), CLDX: 19.06 (+1.34), AMAG: 35.50 (+0.16), AFFX: 8.75 (-0.83)
Look for Shares of Celldex Therapeutics to Potentially Pullback after Yesterday's 28.88% Rise
Comtex SmarTrend(R) - Mon Nov 17, 4:40PM CST
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $16.30 to a high of $19.48. Yesterday, the shares gained 28.9%, which took the trading range above the 3-day high of $15.27 on volume of 22.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CLDX: 19.06 (+1.34)
Earnings Flashback: Since Reporting Quarterly Results 1 Week Ago Celldex Therapeutics Is Down 14.6% (CLDX)
Comtex SmarTrend(R) - Mon Nov 17, 3:58PM CST
When Celldex Therapeutics (NASDAQ:CLDX) reported earnings a week ago on November 4th, 2014, analysts, on average, expected the company to report a loss of $0.33 on sales of $324.0 thousand. Celldex Therapeutics actually reported a loss of $0.31 per share on sales of $1.1 million, beating EPS estimates by $0.02 and beating revenue estimates by $0.8 million. Shares of Celldex Therapeutics have slipped from $16.58 to $14.16, representing a loss of 14.6%, since the company reported earnings 13 days ago.
CLDX: 19.06 (+1.34)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:47AM CST
CADC: 5.11 (-0.32), ANV: 1.76 (-0.28), BONE: 3.14 (-0.02), WLH: 19.17 (+0.01), CLDX: 19.06 (+1.34), ENZY: 8.20 (-0.05), TGEN: 5.54 (-0.68), CHOP: 2.10 (-0.03), MSBF: 9.90 (-0.01), NVGN: 1.75 (-0.05), DWA: 22.54 (+0.06), WHX: 2.26 (-0.08), VYFC: 19.69 (-0.06), VGGL: 3.18 (-0.23), SNSS: 2.18 (+0.11), DNR: 9.85 (-0.16), MOBI: 5.58 (-0.31), VPCO: 1.58 (-0.01), FOLD: 6.68 (-0.07), ATEA: 1.35 (-0.11)
Celldex Therapeutics (CLDX) Stock Surges Following Brain Tumor Immunotherapy Results
at The Street - Mon Nov 17, 10:02AM CST
Shares of Celldex Therapeutics (CLDX) were up in morning trading Monday after the company announced positive results of its immunotherapy in treating a certain type of brain tumor.
CLDX: 19.06 (+1.34)
Celldex Therapeutics: Interim Results For Phase 2 ReACT Trial Are Very Encouraging
Smith On Stocks - at Seeking Alpha - Mon Nov 17, 9:28AM CST
CLDX: 19.06 (+1.34)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:15AM CST
CADC: 5.11 (-0.32), INO: 9.55 (-0.31), CLDX: 19.06 (+1.34), HAL: 48.45 (-0.09), ROX: 1.57 (-0.21), SNSS: 2.18 (+0.11), DNR: 9.85 (-0.16), DWA: 22.54 (+0.06), GSAT: 2.66 (+0.11), CMGE: 25.46 (-0.70), FOLD: 6.68 (-0.07), BHI: 63.27 (-0.28)
Celldex up premarket on positive rindopepimut data
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 7:57AM CST
CLDX: 19.06 (+1.34)
Biotech Equities Technical Coverage - Orexigen Therapeutics, Novavax, Sunesis Pharma, Celldex Therapeutics, and Navidea Biopharma
PR Newswire - Mon Nov 17, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Orexigen Therapeutics Inc. (NASDAQ: OREX), Novavax Inc. (NASDAQ: NVAX), Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, November 14, 2014, the NASDAQ Composite ended at 4,688.54, up 0.18%, the Dow Jones Industrial Average edged 0.10% lower, to finish the day at 17,634.74, and the S&P 500 closed at 2,039.82, up 0.02%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 777.26, down 0.83%, while the index has advanced 9.80% in the last one month. Register for your complimentary reports on these five stocks at:
OREX: 5.72 (+0.10), NAVB: 1.20 (unch), NVAX: 4.96 (-0.05), CLDX: 19.06 (+1.34), SNSS: 2.18 (+0.11)
Celldex Therapeutics' (CLDX) CEO Presents Phase 2 ReACT Interim Data at the Society for Neuro-Oncology Annual Meeting (Transcript)
SA Transcripts - at Seeking Alpha - Fri Nov 14, 10:53PM CST
CLDX: 19.06 (+1.34)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 4:38PM CST
HK: 2.90 (+0.02), NTES: 100.11 (-1.79), CIG: 4.88 (-0.01), TSRO: 30.75 (-0.70), DDD: 36.01 (+0.64), CLDX: 19.06 (+1.34), SCMP: 11.95 (-0.10), BVN: 9.76 (-0.01), ABGB: 15.23 (+0.83), SSE: 10.33 (-0.07)
Interim Update from Randomized Phase 2 ReACT Study of Rindopepimut in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Survival Benefit
GlobeNewswire - Fri Nov 14, 2:35PM CST
-Benefit observed across multiple endpoints in bevacizumab-naïve patients-
CLDX: 19.06 (+1.34)
Celldex Immunotherapy Prolongs Survival for Recurrent Brain Tumor Patients
at The Street - Fri Nov 14, 2:35PM CST
Positive data presented Friday, particularly the statistically significant survival benefit favoring patients treated with rindopepimut, has Celldex planning -- cautiously -- for a conversation with the FDA about accelerated approval.
CLDX: 19.06 (+1.34)
Global Immune Checkpoint Inhibitors Market, 2014-2024: Yervoy, Opdivo and Keytruda to Achieve Blockbuster Status in the Near Future
M2 - Thu Nov 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/fkbg4v/immune_checkpoint) has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering. The Immune Checkpoint Inhibitors Market, 2014-2024 report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for the broad range of cancer. CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic Immune Checkpoint Inhibitor commercially available until other classes recently stepped in. The approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period. Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants. Key Highlights - The market is characterized by the presence of three marketed drugs and 25 drugs in clinical development for oncological indications. This pipeline includes two CTLA-4, eight PD-1 / PD-L1 and 18 novel Immune Checkpoint Inhibitors. The dynamic pipeline also includes several molecules in preclinical / discovery stage; in our research, we identified about 30 such molecules. - BMS, with seven Immune Checkpoint Inhibitors (marketed / clinical development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck and Roche. Many university spin-offs have emerged in the past two years; their early stage research has been backed by venture funding as well. - Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have been the most sought after drug class under development. Though Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market. - Collaborations have helped the market reach its current growth trajectory. Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; 2014 has already seen 12 such collaborations for a number of molecules. - We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2014 - 2024, our forecast suggests that the market will witness an annualized growth rate of 24.1%. Key Topics Covered: 1. Preface 2. Executive Summary 3. Cancer Therapeutics and Immuno-Oncology 4. Current Market Landscape 5. CTLA-4 Inhibitors: Key Molecules and Future Outlook 6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook 7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook 8. Competition in Key Indication Areas 9. Deals and Partnerships 10. Company Profiles 11. Conclusion 12. Appendix 1: Tabulated Data 13. Appendix 2: List of Companies and Organizations Companies Mentioned - Bristol Myer Squibb - AstraZeneca - Merck & Co. - Roche / Genentech - Incyte Corporation - NewLink Genetics - arGEN-X - Seattle Genetics - Pfizer - MacroGenics - Celldex Therapeutics - CureTech - Immutep - Innate Pharma - Sorrento Therapeutics - GlaxoSmithKline - GITR, Inc. For more information visit http://www.researchandmarkets.com/research/fk...checkpoint
MRK: 59.55 (-0.34), INCY: 71.57 (+1.93), CLDX: 19.06 (+1.34), NLNK: 33.18 (+0.52), GSK: 46.32 (+0.04), BMY: 58.55 (-0.15), SRNE: 4.00 (unch)
